Floatz logo

Histrelin

Biochemically Recurrent Prostate Carcinoma

Mayo Clinicprotein_peptidePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the Biochemically Recurrent Prostate Carcinoma cohort.

Asset / SponsorPhaseRating
Degarelix
Baptist Health South Florida
Phase 3BBB
Fluciclovine
NRG Oncology
Phase 3BB
Flotufolastat F-18
Jonsson Comprehensive Cancer Center
Phase 2BB
Relugolix
Baptist Health South Florida
Phase 3BB
LEUPROLIDE
Baptist Health South Florida
Phase 3BB
Apalutamide
Alliance for Clinical Trials in Oncology
Phase 3BB
Durvalumab
University of Washington
Phase 2CCC
Lutetium Lu 177 Psma-10.1
Emory University
Phase 1CC

Same molecule, other indications

Histrelin is also rated in:

prostate adenocarcinomaDormant
BB
Indicative ·
68 / 100
View asset →
prostate cancerDormant
BB
Indicative ·
64 / 100
View asset →
hypogonadismDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →